Russell D A, Thompson R C
Synergen Inc, Boulder.
Curr Opin Biotechnol. 1993 Dec;4(6):714-21. doi: 10.1016/0958-1669(93)90055-2.
Clinical testing of therapies for sepsis that target tumor necrosis factor and interleukin-1 is currently in progress. It is now clear from early clinical results that patients display a heterogeneous response to anti-cytokine therapies that may be related to the stage or severity of disease. Experimental results show that either cytokine may contribute to the metabolic derangements that lead to organ dysfunction in severe sepsis. They also provide a physiological basis for understanding the benefits of anti-cytokine therapy in the most severely ill patients.
目前正在进行针对肿瘤坏死因子和白细胞介素-1的脓毒症治疗方法的临床试验。从早期临床结果来看，现在很清楚的是，患者对抗细胞因子疗法表现出异质性反应，这可能与疾病的阶段或严重程度有关。实验结果表明，这两种细胞因子都可能导致严重脓毒症中导致器官功能障碍的代谢紊乱。它们还为理解抗细胞因子疗法对重症患者的益处提供了生理基础。
